Jun 22, 2023, 18:35
Generic manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of Novartis’ nilotinib – Medicines Patent Pool
Breaking | 4 generic manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of Novartis,’ nilotinib for the treatment of chronic myeloid leukaemia.
The four generic manufacturers companies include:
- Eugia Pharma Specialities Ltd (INDIA)
- Hetero (INDIA)
- Dr. Reddy’s Laboratories (INDIA)
- PT. Brightgene Biomedical Indonesia (INDONESIA)
Source: /Linkedin
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 1, 2024, 19:12
Nov 1, 2024, 17:46
Nov 1, 2024, 17:41
Nov 1, 2024, 17:27